GLP1R and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are recently introduced drug classes for the treatment of type 2 diabetes (T2D).